[6] In April, additional warning letters targeted unapproved peptides
106 Oliva-DamasoE.Oliva-DamasoN.Rodriguez-EsparragonF.PayanJ.Baamonde-LabordaE.Gonzalez-CabreraF.et al (2019)
The first is replacement of Ala with the non-proteinogenic amino acid 2- aminoisobutyric acid (Aib) at position 2
Electronic databases including PubMed, Embase, and Web of Science were searched from inception until August 2025 using keywords such as GLP-1 receptor agonist, diabetic retinopathy, glaucoma, age-related macular degeneration, ocular disease, and neuroprotection. The search focused on identifying preclinical studies, large-scale retrospective cohort studies, and post-hoc analyses of major clinical trials that evaluated the utility and potential mechanisms of GLP-1RAs in ophthalmic diseases
In this review, the new class of antihyperglycaemic agents with incretin effect, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (IDPP-4), and novel sodium-glucose cotransporter 2 inhibitors (ISGLT2) that increase renal glucose excretion will be analyzed
.png&w=828&q=100)
